This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson
by Zacks Equity Research
Can-Fite (CANF) stock up 7% as the liver cancer patient achieves a complete response and overall survival of 6.9 years upon continued treatment with namodenoson in a phase II study.
Can-Fite Biopharma Ltd (CANF) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Can-Fite Biopharma Ltd (CANF), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Best Momentum Stocks to Buy for October 27th
by Zacks Equity Research
VRT, PGR and CANF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 27, 2023.
New Strong Buy Stocks for October 27th
by Zacks Equity Research
MTRX, OPI, CANF, ENLV and RAIL have been added to the Zacks Rank #1 (Strong Buy) List on October 27, 2023.
Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer
by Zacks Equity Research
Can-Fite's (CANF) shares rise 11.4% as it reveals its plans of submitting an investigational new drug application. The idea is to initiate expansion studies for namodenoson to treat pancreatic carcinoma.
All You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to Buy
by Zacks Equity Research
Can-Fite Biopharma Ltd (CANF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study
by Zacks Equity Research
A mid-stage study data shows that treatment with PDS Biotech's (PDSB) lead candidate in advanced HPV-positive cancer patients achieved a median overall survival of 21 months.
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA
by Zacks Equity Research
Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.
Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Pacira's (PCRX) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.
Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Corcept's (CORT) third-quarter 2022 earnings beat estimates while revenues miss the same. The company tightens its revenue guidance for 2022. Shares down in after-hours trading.
All You Need to Know About CanFite Biopharma Ltd (CANF) Rating Upgrade to Buy
by Zacks Equity Research
CanFite Biopharma Ltd (CANF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is CanFite Biopharma Ltd (CANF) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how CanFite Biopharma Ltd (CANF) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.
Can-Fite (CANF) Files Patent Applications for Namodenoson
by Zacks Equity Research
Can-Fite (CANF) files patent applications in several countries for treating all advanced solid tumors. The filing comes after Can-Fite's drug cleared all tumor lesions in advanced liver cancer.
Company News for Dec 21, 2021
by Zacks Equity Research
Companies in the news are: ITCI, VRS, CANF, FSM
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) earnings and revenues beat estimates in the second quarter of 2021. The company raised its financial guidance for 2021.
Pacira's (PCRX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings and revenues in the second quarter of 2021 surpass estimates. Exparel sales surge year over year.
Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer
by Zacks Equity Research
The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.
Catalyst (CPRX) Thrives on Firdapse But Overdependence Concerns
by Zacks Equity Research
Catalyst's (CPRX) Firdapse is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch. Sole dependence on Firdapse for growth remains a concern.
Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study
by Zacks Equity Research
Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.
Jazz Pharma (JAZZ) Gets FDA Approval for Leukemia Drug Rylaze
by Zacks Equity Research
Jazz Pharma (JAZZ) gets FDA approval for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.
New Strong Sell Stocks for April 19th
by Zacks Equity Research
PAC, CANF, GOL, HRTH, and INLX have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2021
Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients
by Zacks Equity Research
The FDA approves Pacira's (PCRX) Exparel for use in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia.
Spectrum's (SPPI) NSCLC Drug Gets FDA's Fast Track Designation
by Zacks Equity Research
The FDA grants a Fast Track designation to Spectrum Pharmaceuticals' (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations.
CanFite Biopharma Ltd (CANF) Upgraded to Buy: Here's Why
by Zacks Equity Research
CanFite Biopharma Ltd (CANF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.